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Summary
 
The molecular mechanisms that contribute to an eosinophil-rich airway inflammation in
asthma are unclear. A predominantly T helper 2 (Th2)-type cell response has been documented
in allergic asthma. Here we show that mice deficient in the p50 subunit of nuclear factor (NF)-
 
k
 
B are incapable of mounting eosinophilic airway inflammation compared with wild-type
mice. This deficiency was not due to a block in T cell priming or proliferation in the p50
 
2/2
 
mice, nor was it due to a defect in the expression of the cell adhesion molecules VCAM-1 and
ICAM-1 that are required for the extravasation of eosinophils into the airways. The major de-
fects in the p50
 
2/2
 
 mice were the lack of production of the Th2 cytokine interleukin 5 and the
chemokine eotaxin, which are crucial for proliferation and for differentiation and recruitment,
respectively, of eosinophils into the asthmatic airway. Additionally, the p50
 
2/2
 
 mice were defi-
cient in the production of the chemokines macrophage inflammatory protein (MIP)-1
 
a
 
 and
MIP-1
 
b
 
 that have been implicated in T cell recruitment to sites of inflammation. These results
demonstrate a crucial role for NF-
 
k
 
B in vivo in the expression of important molecules that
have been implicated in the pathogenesis of asthma.
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A
 
sthma is a chronic inflammatory disease of the lower
airways that causes airway hyperresponsiveness to a
wide variety of specific and non-specific stimuli. Both the
prevalence and severity of asthma is increasing at an alarm-
ing rate in developed countries. Bronchoalveolar lavage
(BAL)
 
1
 
 and biopsy of patients with mild to moderate asthma
has provided impressive evidence for complex airway in-
flammation in asthma (1–3). The most striking and consis-
tent pathophysiology, at least in atopic asthma, is damage to
the bronchial epithelium and infiltration of the bronchial
wall and lumen by eosinophils (2, 4–10). Eosinophils are
conspicuous in the airways of the majority of asthmatics,
from the mildest to the most severe, and the number of
eosinophils in the peripheral blood and airways correlates
with hyperresponsiveness and clinical severity (2, 4–11).
Eosinophils can generate an array of potent proinflamma-
tory mediators, including the cytotoxic proteins preformed
and stored in the eosinophil granules such as major basic
protein and eosinophil cationic protein, eicosanoid com-
pounds including leukotriene (LT)C
 
4
 
, LTD
 
4
 
, platelet acti-
vating factor, and prostaglandins (PG)E
 
1
 
 and E
 
2
 
, and finally
proinflammatory cytokines.
It is now generally accepted that the eosinophil-rich in-
flammatory response that mediates airway tissue damage in
atopic individuals arises from aberrant T cell–mediated im-
mune responses to a range of inhaled allergens that are
seemingly ignored by nonresponsive “normal” individuals
(3, 8, 12–14). Cytokine expression profiles of allergen-spe-
cific T cell clones isolated from atopics are skewed toward a
Th2-like profile compared with a Th1-like profile in non-
atopics (for review see references 15, 16). The cytokine
IL-5, produced by Th2 cells, is now known to be the cen-
tral mediator in the regulation of eosinophilic inflammation
in asthma (1, 17–19). IL-5 is intimately associated with sev-
eral features of eosinophil biology; it not only regulates the
proliferation, differentiation, and activation of eosinophils
(20–22), it also provides an essential signal for the rapid
mobilization of eosinophils from the bone marrow and co-
operates with the chemokine eotaxin in the homing of the
eosinophils to sites of allergic inflammation (23). Due to
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; BALF, BAL
fluid; EMSA, electrophoretic mobility shift assay; H&E, hematoxylin and
eosin; ICAM, intercellular adhesion molecule; MCP, monocyte chemo-
tactic protein; MIP, macrophage inflammatory protein; NF, nuclear fac-
tor; PLP, paraformaldehyde; RANTES, regulated on activation, normal
T cell expressed and secreted; RT, reverse transcription; VCAM, vascular
cell adhesion molecule.
  
1740
 
NF-
 
k
 
B Is Essential for Allergic Airway Inflammation
 
the proposed central role of eosinophils in asthma and aller-
gic disease, there is considerable interest in the molecular
mechanisms that mediate the expression of genes that pro-
mote eosinophilia such as IL-5 and eotaxin.
The transcription factor nuclear factor (NF)-
 
k
 
B plays an
important role in regulating many inflammatory processes
(24–29). NF-
 
k
 
B proteins control the expression of multi-
ple genes involved in immune responses such as those en-
coding proinflammatory cytokines and chemokines (24–
26, 28, 29). The NF-
 
k
 
B proteins belong to the Rel family
of proteins. So far, five members of the NF-
 
k
 
B family have
been described: c-Rel; NF-
 
k
 
B1 (p50); NF-
 
k
 
B2 (p52);
RelA (p65); and RelB (24–26). The classic NF-
 
k
 
B com-
plex is a heterodimer of two polypeptide subunits, p50 and
RelA (p65). Most members of the NF-
 
k
 
B family can form
homo- or heterodimers (except for RelB, which only
forms heterodimers with p50 or p52) that bind slightly dif-
ferent 
 
k
 
B motifs (24–26). (p50)
 
2
 
 has been shown to act as a
dominant repressor of transcription from specific 
 
k
 
B sites
(30–32). We have recently shown that (p50)
 
2
 
 behaves as a
selective repressor of RANTES (regulated on activation,
normal T cell expressed and secreted) gene expression (33).
It appears that in vivo (p50)
 
2
 
 functions as an activator in
certain tissues such as the thymus but acts as a repressor in
others present in peripheral lymphoid organs and in mac-
rophages, such as T cells (34).
Studies of gene knockout animals indicate that the dif-
ferent Rel family proteins are not functionally redundant.
For example, knockout of the RelA (p65) gene in mice
causes embryonic lethality apparently due to extensive ap-
optosis in the liver (35). On the other hand, p50
 
2/2
 
 mice
develop normally and express normal mature B and T cell
subsets (36). However, the B cells in these mice are se-
verely limited in their functions. They do not proliferate in
response to bacterial LPS (37), and furthermore, p50
 
2/2
 
 B
cells are defective in IgG3, IgE, and IgA class switching and
display markedly reduced levels of germline C
 
H
 
g
 
3 and C
 
H
 
e
 
RNA but normal levels of germline C
 
H
 
g
 
1 and C
 
H
 
a
 
 RNA
(37).
Although gene knockout studies have eliminated notions
of simple redundancy of the different NF-
 
k
 
B proteins, little
is known about the specific role of these proteins in the
pathogenesis of different inflammation-associated disease
states in vivo. For example, whether the characteristic eosin-
ophilic inflammation observed in asthma is an NF-
 
k
 
B–
dependent phenomenon was not known before this study.
We used p50
 
2/2
 
 mice in a murine model of airway inflam-
mation to investigate the role of NF-
 
k
 
B in the pathogene-
sis of eosinophilic airway inflammation, which, as we and
others have shown, is predominantly a CD4
 
1
 
 T cell–domi-
nated process (18, 38–41). We show that the p50
 
2/2
 
 mice
are devoid of eosinophilic airway inflammation upon anti-
genic stimulation. The lack of inflammation was not due to
insufficient CD4
 
1
 
 
 
T cell priming. Also, IL-2 production,
which is believed to be an NF-
 
k
 
B–regulated process, was
unimpaired in the p50
 
2/2
 
 mice and the cells proliferated as
efficiently as the wild-type cells in response to antigen. The
absence of inflammation also was not due to a lack of ex-
 
pression of vascular cell adhesion molecule (VCAM)-1 and
intercellular adhesion molecule (ICAM)-1, which have
been shown to be important for eosinophil homing. A ma-
jor deficiency in the p50
 
2/2
 
 mice was the absence of IL-5
production by the CD4
 
1
 
 T cells upon antigenic stimula-
tion. Another difference between the two types of mice
was the lack of expression of the eosinophilic chemoattrac-
tant eotaxin at both the RNA and the protein level in the
lungs of p50
 
2/2
 
 mice. The expression of the chemokine
genes macrophage inflammatory protein (MIP)-1
 
a
 
 and
MIP-1
 
b
 
, which have been implicated in T cell chemotaxis,
was also deficient in the p50
 
2/2
 
 mice. Taken together, this
is the first report that demonstrates an essential role for NF-
 
k
 
B in the regulation of important molecules that regulate
eosinophilic inflammation in vivo. Furthermore, our stud-
ies also demonstrate a dissociation between the expression
of the IL-4 and IL-5 genes, both of which are expressed by
Th2-type cells.
 
Materials and Methods
 
Mice.
 
The p50
 
2/2
 
 and wild-type mice were on a C57BL6/
129 background and the generation of the p50
 
2/2
 
 mice has been
described by Sha et al. (36). Mice between 6 and 8 wk of age
were purchased from The Jackson Laboratory (Bar Harbor, ME).
The mice were housed in a pathogen-free facility at Yale Univer-
sity School of Medicine.
 
Sensitization and Challenge of Mice.
 
Mice were sensitized and
challenged essentially as described by Kung et al. (42). Mice were
sensitized with 10 
 
m
 
g of OVA (Sigma Chemical Co., St. Louis,
MO) and 1 mg of alum (Resorptar; Intergen Co., New York,
NY) intraperitoneally on days 0 and 5. Sham-immunized mice
received alum alone. On day 12, mice were challenged by expo-
sure to an aerosol of 1% OVA in PBS twice for 1 h each at an in-
terval of 4 h. Inhalation was carried out in a plastic chamber (27 
 
3
 
20 
 
3 
 
10 cm). The inhalation chamber that we use has an attach-
ment to allow entry of the aerosol from an ultrasonic nebulizer
(1–5 
 
m
 
M particles by manufacturer’s specifications, Model no.
NE-U07; Omron, Vernon Hills, IL). The other end of the box
has two small holes for the maintenance of continuous airflow.
 
BAL.
 
BAL was performed at 24 h after aerosol challenge.
Mice were anesthetized and the lungs and heart were surgically
exposed. The trachea were cannulated and the lungs were la-
vaged twice with 1-ml aliquots of PBS. The live cells (excluded
trypan blue) recovered were counted in a hemocytometer.
Cytospin preparations of BAL cells were stained with Diff-Quik
(Baxter HealthCare Corp., Miami, FL) and cell differentials were
enumerated based on morphology and staining profile.
 
Lung Histology.
 
Lungs were prepared for histology by perfus-
ing the animal through the right ventricle with PBS to remove all
blood. Lungs were then inflated to constant pressure with 1.0 ml
of fixative instilled through a tracheostomy tube as described pre-
viously (43). For staining with hematoxylin and eosin (H&E),
lungs were fixed in 10% formalin and embedded in paraffin.
5-
 
m
 
M sections were mounted on slides and stained with H&E
according to established procedures (41, 43). For immunohis-
tochemistry, lungs were perfused and fixed in 0.001 M periodate/
0.075 M lysine/1% paraformaldehyde (PLP) and processed essen-
tially as described previously (44). In brief, lungs were fixed in
PLP overnight at 4
 
8
 
C with the tracheostomy tube left in place
while in PLP. The tissue was washed three times for 5 min each 
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in 0.1 M cold phosphate buffer. The tissue was then treated suc-
cessively with 10 and 20% sucrose (in phosphate buffer) for 20
min each. Lungs were inflated via the tracheostomy tube with 1
ml of 40% OCT diluted in PBS (tissue freezing medium; Elec-
tron Microscopy Sciences, Fort Washington, PA). Lungs were
embedded in 100% OCT in cryomold and plunged into a 2-methyl-
butane bath precooled on dry ice. Tissues were stored at 
 
2
 
70
 
8
 
C
until sectioning. Sections were mounted onto slides. Slides were
soaked in wash buffer (0.1 M phosphate buffer plus 0.01% Triton
X-100) for 10 min and blocked with 3% BSA in wash buffer.
Biotinylated primary antibodies (anti–ICAM-1 antibody; catalog
number 01542D; anti–VCAM-1 antibody; catalog number 01812D)
and the isotype-matched control antibodies were all purchased from
PharMingen (San Diego, CA). The anti–VCAM-1 antibody was
used at a 1:50 dilution, whereas the anti–ICAM-1 antibody was
used at a 1:150 dilution in 1% BSA. The antibodies were left on
the slides for 1.5 h at 25
 
8
 
C. The slides were successively washed
in wash buffer and 0.1 M Tris, pH 7.5. The tissues were incu-
bated with streptavidin-alkaline phosphatase (Zymed, San Fran-
cisco, CA) for 30 min. The tissues were washed three times for
2 min each time in 0.1 M Tris, pH 7.5, and developed with Fast
Red until staining was adequate. The slides were washed three
times in double-distilled water and counterstained with hema-
toxylin.
 
Preparation of Nuclear Extracts from Whole Lung and Electrophoretic
Mobility Shift Assays.
 
To prepare nuclear extracts from lung tis-
sue, the lungs were snap frozen in liquid N
 
2
 
 and pulverized. The
following steps all were carried out at 4
 
8
 
C. The lung powder was
homogenized in 5 ml of solution A (10 mM Hepes, pH 7.9, 150
mM NaCl, 1 mM EDTA, 0.5 mM PMSF, and 0.6% NP-40) in a
Dounce tissue homogenizer (Wheaton, Millville, NJ) and centri-
fuged at 800 
 
g
 
 for 30 s to remove cellular debris. The supernatant
was left on ice for 5 min and then centrifuged at 2000 
 
g
 
 for 5 min.
The pelleted nuclei were resuspended in 150–200 
 
m
 
l of solution
B (20 mM Hepes, pH 7.9, 420 mM NaCl, 1.2 mM MgCl
 
2
 
, 0.2
mM EDTA, 0.5 mM dithiothreitol, 0.5 mM PMSF, 2 mM benz-
amidine, 25% glycerol, and a mixture of protease inhibitors (Boeh-
ringer Mannheim, Indianapolis, IN) for 20 min. The lysed nuclei
were briefly centrifuged at 16,000 
 
g
 
. The supernatant was ali-
quoted, snap frozen in a dry ice/methanol bath and stored at
 
2
 
70
 
8
 
C until further use. A 
 
32
 
P-labeled oligonucleotide contain-
ing the NF-
 
k
 
B sequence present in the Ig
 
k
 
B gene was used as the
probe in electrophoretic mobility shift assays (EMSAs). The bind-
ing reactions were analyzed by electrophoresis on 6% native poly-
acrylamide gels (acrylamide/bisacrylamide
 
 5 
 
30:1). Electrophore-
sis was carried out at 150 V in 0.5
 
3 
 
TBE (1
 
3 5 
 
0.05 M Tris base,
0.05 M boric acid, and 1.0 mM EDTA) at 4
 
8
 
C. Gels were dried
and subjected to autoradiography.
 
RNA Isolation and Ribonuclease Protection Assays.
 
Total RNA
was isolated from lung tissue using TRIzol Reagent (GIBCO
BRL, Gaithersburg, MD) according to the manufacturer’s in-
structions. Each whole fresh lung was homogenized in 4 ml of
TRIzol reagent using Tissumizer (Tekmar Co., Cincinnati, OH)
and centrifuged to remove cellular debris. The RNA pellet was
resuspended in nuclease-free H
 
2
 
O. 10 
 
m
 
g of total lung RNA
from each mouse was used in ribonuclease protection assay
(RPA) using the RPA II Kit (Ambion, Austin, TX). The murine
cytokine template set mCK-5 (PharMingen) was used to obtain
radiolabeled antisense RNA probes for RANTES, eotaxin, MIP-
1
 
a
 
, MIP-1
 
b
 
, MIP-2, IP-10, monocyte chemotactic protein
(MCP)-1, L32, and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). In vitro transcription was carried out by incubation in
a buffer containing 10 mM ATP, 10 mM CTP, 10 mM GTP,
250 
 
m
 
Ci 
 
a
 
-[
 
32
 
P]UTP (800 Ci/mmol, 10 mCi/mmol; Amersham
Pharmacia Biotech, Arlington Heights, IL) and T7 RNA poly-
merase in transcription buffer (MAXIscript Kit; Ambion). The
mixture was incubated at 37
 
8
 
C for 60 min and then treated with
DNase I at 37
 
8
 
C for 30 min. The mixture was extracted with a
mixture of phenol and chloroform, and the RNA was precipi-
tated with ethanol and collected by centrifugation at 4
 
8
 
C. The
RNA was resuspended in 50 
 
m
 
l hybridization buffer and diluted
to 3 
 
3 
 
10
 
5 cpm/ml, and 2 ml was used per reaction. The lung
RNA samples (10 mg from each mouse) were dried in a vacuum
evaporator and resuspended in 8 ml hybridization buffer. The
RNA was annealed to the probe by incubating successively at
958C for 3 min and at 568C overnight in a total volume of 10 ml.
RNase was added to each sample for removal of single-stranded
RNA and RNase digestion was carried out at 308C for 45 min.
The protected RNA duplexes were purified by phenol/chloro-
form extraction and ethanol precipitation. The pelleted RNA
was resuspended in 5–6 ml of gel loading buffer, incubated at
958C for 3 min, quickly quenched on ice and analyzed by elec-
trophoresis on 5% polyacrylamide/8 M urea gels. The gels were
dried and subjected to autoradiography.
Cell Proliferation Assays. Mice were sensitized as above by in-
traperitoneal injections of OVA plus alum on days 0 and 5.
Spleens were harvested on day 12 and CD41 T cells were pre-
pared by negative selection using mAbs to CD8, class II MHC
I-A, and anti-Ig–coated magnetic beads (Collaborative Research,
Bedford, MA). Syngeneic T cell–depleted splenocytes were used as
APCs that were prepared by negative selection using antibodies to
CD4 (GK1.5), CD8, Thy-1, and treatment with rabbit comple-
ment and mitomycin C as described previously (41). 5 3 105 CD41
T cells (pooled from two mice in each group) together with 5 3
105 APCs were cultured with OVA (0.1–100 mg/ml) in Bruff’s me-
dium supplemented with 5% FCS. Cultures were incubated for
72 h, supernatants were collected for cytokine analyses and cultures
were pulsed with 1 mCi of methyl-[3H]thymidine/well. After incu-
bation at 378C for 24 h, triplicate wells were harvested onto glass fil-
ters and incorporated radioactivity was measured in a beta counter.
The background was subtracted from the results.
Cytokine Assays. IL-2, IL-4, IL-5, and IFN-g protein levels
in culture supernatants and in BAL and eotaxin protein levels in
BAL were determined by ELISA. The lower limits of detection
for the cytokines were: IL-2, 3 pg/ml; IL-4, 5 pg/ml; IL-5, 5 pg/
ml; IFN-g, 15 pg/ml (Endogen, Cambridge, MA); and for the
chemokine eotaxin, 3 pg/ml (R & D, Minneapolis, MN).
Reverse Transcription-PCR. RNA isolated from the OVA-
stimulated CD41 T cells were used in reverse transcription (RT)-
PCR. To synthesize cDNA, random primers (100 pmol) were
annealed to 1 mg of total RNA by incubation at 688C for 10 min.
RT was carried out by adding dNTP, 8 U of an RNase inhibitor
(RNasin), 0.2 mM dithiothreitol, and 200 U SuperScript II
(GIBCO BRL) and buffer and by incubating at 378C for 10 min,
at 428C for 50 min and finally at 948C for 2 min. The cDNAs
synthesized were used in PCR. PCR was performed using
primer sets corresponding to the murine IL-4 and IL-5 genes.
The sequences of the primer were: IL-4; 59-CAT CGG CAT
TTT GAA CGA GGT CA-39 (forward) and 59-CTT ATC GAT
GAA TCC AGG CAT CG-39 (reverse); IL-5; 59-CTC ACC
GAG CTC TGT TGA CAA G-39 (forward) and 59-GAA CTC
TTG CAG GTA ATC CAG G-39 (reverse). The reactions were
assembled in HotStart tubes (Molecular Bio-Product, Inc., San
Diego, CA) as follows: first the lower layer mix was added that
included 10mM dNTP, 13 Pfu (Stratagene, La Jolla, CA) reac-
tion buffer and primers (50 pmol). The mixture was heated to1742 NF-kB Is Essential for Allergic Airway Inflammation
908C for 30 s and cooled down to room temperature, and then
the upper layer that included cDNA (1–2 ml), 1.25 U of Pfu DNA
polymerase (Stratagene) and 13 Pfu buffer was added. For PCR,
the samples were first heated to 948C for 2 min (for denaturation)
and the PCR cycle conditions were: 948C for 45 s, 648C for 45 s,
and 728C for 1 min. The reactions were terminated by incubation
at 728C for 7 min to complete chain extensions. The products
were analyzed by electrophoresis on 1% agarose gels.
Results
Activation of NF-kB Complexes By Antigen (OVA) in the
Lungs of Wild-type but Not p502/2 Mice. To investigate the
effects of antigenic (OVA) stimulation on NF-kB activa-
tion in the whole lung, wild-type and p502/2 mice were
sensitized and challenged with OVA (hereafter referred to
as OVA/OVA). 2 h after challenge with OVA, mice were
killed and nuclear extracts were prepared from the whole
lung. The nuclear extracts were used in EMSAs using an
oligonucleotide containing a consensus binding sequence
for NF-kB. As shown in Fig. 1, lane 1, nuclear extracts pre-
pared from sham-sensitized and OVA-challenged (Alum/
OVA) mice did not display appreciable DNA-binding
activity. On the other hand, nuclear extracts prepared from
the lungs of mice sensitized and challenged with OVA
(OVA/OVA) formed three distinct complexes. In the case
of p502/2 mice, no DNA–protein complex was observed
with nuclear extracts from control mice (Alum/OVA).
With extracts prepared from OVA/OVA mice, only the
fastest migrating complex (shown by an arrow) was de-
tected. We used specific antibodies to determine the com-
position of the different polypeptide complexes. Formation
of complex I was affected by both anti-p50 and anti-p65
antibodies, suggesting that it contained the classic p50–p65
heterodimer (Fig. 1, lanes 6 and 10). Complex II formation
was affected only by the anti-p50 antibody (Fig. 1, lane 6).
Also, complex II comigrated with the complex formed
with recombinant p50, confirming that it contained (p50)2.
The intensity of the complex shown by an arrow was vari-
able in different experiments. This complex was not super-
shifted by the anti-p50 or the anti-p65 antibody, nor by
antibodies against other Rel proteins (data not shown), and
most likely represents nonspecific binding. Oct-1–binding
activity, used as a loading control, was comparable in all the
lanes (data not shown). Thus, the EMSAs demonstrated the
presence of active NF-kB dimers containing p50 in the lungs
of antigen-challenged wild-type mice and their absence in
the lungs of similarly challenged p502/2 mice.
Absence of Antigen-Induced Eosinophilic Airway Inflammation
in the Lungs of the p502/2 Mice. To assess the effect of in-
haled antigen on airway inflammation in the wild-type (1/1)
and p502/2 ( 2/2) animals, mice were killed 24 h after
aerosol challenge with OVA and the lungs were examined
histologically. As shown in Fig. 2 a, wild-type mice dis-
played a prominent inflammatory response. Eosinophilic
inflammation was widespread with both perivascular and
peribronchiolar infiltration. On the other hand, the p502/2
mice had no eosinophilic inflammation in their airways
upon antigen challenge (Fig. 2 b). In some p502/2 mice, a
few patchy areas of a low degree of inflammation were
noted in which eosinophils or neutrophils were barely de-
tectable. The lungs of animals sham-sensitized with alum
only and challenged with OVA (Fig. 2, c and d, respec-
tively) were totally devoid of any inflammation.
The impressive difference in lung inflammation between
the wild-type and p502/2 mice was also observed in the
BAL fluid (BALF) recovered from the animals. The total
cell count in the BALF recovered from the p502/2 mice
upon antigen challenge was 10-fold lower than that in the
BALF derived from the wild-type mice (Fig. 3 A). After Figure 1. Induction of NF-kB
activity in the lungs of p501/1
but not p502/2 mice. Mice were
either sensitized with OVA1
alum followed by an aerosol
challenge with OVA (OVA/
OVA) or sham-sensitized with
alum only and OVA-challenged
(Alum/OVA). Nuclear extracts
prepared from the lungs of ani-
mals subjected to Alum/OVA or
OVA/OVA were used for EM-
SAs. A 32P-labeled oligonucleotide
containing a consensus NF-kB–
binding sequence was used to
detect the kB-binding activities.
Binding reactions were carried
out in the presence or absence of
specific antibodies (Ab) as indi-
cated. In parallel reactions, binding reactions were also carried out with
recombinant p50 (rp50; Promega Corp., Madison, WI). The probe was
incubated with rp50 in the presence or absence of anti-p50 Ab (lane 9) or
anti-p65 Ab (lane 10; used as a control). The p50 homodimer and the
p50–p65 heterodimer are indicated as complexes I and II, respectively.
Nonspecific binding to the probe is shown by an arrow and the intensity
of this complex was variable in different experiments. Binding reactions
were analyzed by electrophoresis on 6% native polyacrylamide gels as de-
scribed previously (33, 90).
Figure 2. Absence of airway inflammation in p502/2 mice. Lung sec-
tions of p501/1 or p502/2 mice either OVA/OVA-treated (a and b, re-
spectively) or ALUM/OVA-treated (c and d, respectively) were subjected
to H&E staining (503). p501/1 OVA/OVA-treated mice had impressive
peribronchiolar and perivascular eosinophilic inflammation. No eosino-
philic infiltrates were detected in lung tissue from p502/2 mice.1743 Yang et al.
antigen provocation, although there was an z2,000-fold
increase in the number of eosinophils in the airways of the
wild-type mice (compared with sham-sensitized animals),
the net increase in eosinophils was only 10-fold in the air-
ways of the p502/2 mice (Fig. 3 A). In addition to a
blunted eosinophil recruitment, neutrophil recruitment
was also markedly attenuated in the airways of the p502/2
mice. Also, the number of lymphocytes recovered from the
airways of the p502/2 mice was z5–6-fold less than that
obtained from the wild-type mice (Fig. 3 A). The cells in
the BALF recovered from the p502/2 mice contained pre-
dominantly monocytes/macrophages similar to those ob-
served in the BALF derived from control mice that were
sham-sensitized and challenged with OVA (Fig. 3 A).
We also examined cytokine levels in the airways of these
mice. As shown in Fig. 3 B, the predominant cytokines
present in the BALF obtained from the wild-type mice
were of the Th2 type as was expected in this model. First,
with the exception of IL-2, all other cytokines were
present at lower levels in the airways of the p502/2 mice as
was expected from the deficient airway inflammation in
these mice after antigen challenge. Second, IL-4 was de-
tectable in the BALF of p502/2 mice, albeit at lower levels
compared with those in the wild-type mice. The lower
level of IL-4 in the BALF of the p502/2 mice is probably
due to fewer lymphocytes in the airways of these mice, as
Th2 lymphocytes are the major source of this cytokine in
asthma and allergic inflammation. The other Th2-type cy-
tokine, IL-5, was barely detectable in the BALF of the
p502/2 mice (Fig. 3 B). Thus, the production of IL-5 ap-
peared to be more severely affected by the absence of the
p50 subunit of NF-kB than the production of IL-4.
Basal Eosinophil Counts in the p502/2 Mice. We investi-
gated the basal level of eosinophils in the wild-type and the
p502/2 mice. As shown in Table 1, the level of eosinophils
in the bone marrow and peripheral blood of p502/2 mice
was comparable to that in the controls.
Expression of Cell Adhesion Molecules VCAM-1 and
ICAM-1 in the Airways of Wild-type and p502/2 Mice. We
investigated the expression of the cell adhesion molecules
VCAM-1 and ICAM-1 in the airways of wild-type and
p502/2 mice by immunohistochemistry since both of these
molecules have been implicated in eosinophil extravasation
from the blood vessel into the airways (45). After OVA
challenge, the animals were killed and the lungs were fro-
zen for immunohistochemistry. As shown in Fig. 4 A,
upon OVA challenge, strong expression of VCAM-1 was
evident on the vascular endothelium in both the wild-type
and p50-deficient mice (Fig. 4 A, a and b, respectively). No
staining was observed in the lungs of the control animals
sensitized with alum and challenged with OVA (Fig. 4. A, c
and d). Also, no reaction was observed with the isotype-
matched control antibody (Fig. 4 A, e and f, respectively).
The expression of ICAM-1 was also similar in the wild-
type and p502/2 mice (Fig. 4 B). Strong constitutive
ICAM-1 expression on the alveolar epithelium and some-
what weaker expression on the vascular endothelium was
Figure 3. Decreased leukocyte infiltration and cytokine production in
the airways of p502/2 mice. (A) Total and differential cell counts in the
BAL of wild-type and p502/2 mice. Mean cell counts 6 SEM are shown
(n 5 3 per group). Results shown are representative of three experiments.
(B) Estimation of cytokines in BALF by ELISA. Results shown are mean 6
SEM for three mice in each group.
Table 1. Basal Eosinophil Counts in the p501/1 and 
p502/2 Mice
Bone marrow Peripheral blood
%%
p501/1 mice 7.2 6 0 2.25 6 0.75
p502/2 mice 5.0 6 0.8 3.35 6 0.35
Bone marrow cells were obtained by flushing the cavity of a single fe-
mur from each mouse with serum-free RPMI 1640 medium containing
heparin (10 U/ml). Cells derived from the bone marrow and peripheral
blood were suspended in lysis buffer (Pharm Lyse; PharMingen) for
2 min for lysis of the red blood cells. The cells were washed twice in
PBS and cytospin preparations were stained with Diff-Quik. Shown are
the number of eosinophils determined as a percentage of the total num-
ber of leukocytes 6 SEM.1744 NF-kB Is Essential for Allergic Airway Inflammation
noted in both wild-type and p50-deficient mice (Fig. 4 B, c
and d, respectively) and there was no significant change in
the pattern of staining after OVA challenge (Fig. 4 B, a and
b). Again, no staining was observed with the control anti-
body (Fig. 4 B, e and f ).
Differential Chemokine Gene Expression in the Lungs of
p502/2 and Wild-type Mice. Since chemokines have been
shown to be important for the recruitment of leukocytes to
sites of inflammation, we investigated the expression of key
chemokines that have been implicated in eosinophil
chemotaxis. Mice were killed at different time points after
OVA challenge, and RNA isolated from the lungs of these
mice was subjected to RNase protection assays for the ex-
pression of different chemokine genes. The expression of
RANTES mRNA was found to be constitutive in the
lungs of both wild-type and p502/2 mice and the expres-
sion remained unchanged after challenge with OVA (Fig. 5
A). In the lungs of p501/1 mice, the expression of mRNAs
for eotaxin, MIP-1a, MIP-1b, IP-10, and MCP-1 was de-
tectable early, at 2 h after OVA challenge, and the steady-
state levels of these messages were higher at 4 h after chal-
lenge (data not shown). At 24–36 h after challenge, eotaxin
and MIP-1a mRNAs continued to be expressed at a high
level in the wild-type mice. In the p502/2 mice a different
pattern of chemokine mRNA expression was detected.
The expression of eotaxin or MIP-1a or MIP-1b mRNA
was barely detectable in these mice at all time points. How-
ever, the expression of IP-10 mRNA was stronger in the
p502/2 mice compared with that in the wild-type mice at
all time points tested. The expression of MCP-1 mRNA
was comparable in the wild-type and p502/2 mice at all
time points. Given the importance of eotaxin as an eosino-
phil chemoattractant, we have also tested the level of
eotaxin protein in the BALF in the OVA-challenged wild-
type and p502/2 mice. As shown in Fig. 5 B, eotaxin pro-
tein was readily detected at 24 h in the BALF recovered
from the wild-type mice but was barely detectable in that
obtained from the p502/2 mice.
Proliferative Responses and Cytokine Production by CD41 T
Cells in Wild-type and p502/2 Mice. We next examined
whether the absence of airway inflammation in the p50-defi-
cient mice in response to antigen challenge was due to a de-
Figure 4. Expression of VCAM-1 and ICAM-1 in the lungs of both p501/1 and p502/2 mice. Lung sections of ALUM/OVA or OVA/OVA-treated
animals were stained with (A) anti–VCAM-1 or (B) anti–ICAM-1 mAb and counterstained with hematoxylin. In both cases, lung sections from OVA/
OVA- or ALUM/OVA-treated p501/1 and p502/2 animals were incubated either with specific antibody (OVA/OVA, a and b respectively; ALUM/
OVA, c and d, respectively) or with isotype-matched control antibody (e and f, respectively). VCAM-1 staining (red) was observed on the vascular endo-
thelium of both wild-type and p502/2 mice. In both groups of mice, strong constitutive ICAM-1 staining was observed on the alveolar epithelium and
weaker staining on the vascular endothelium, and the staining pattern remained unchanged upon challenge with OVA. No staining was observed with
the control antibodies in either case (lung sections used were from OVA/OVA mice). Filled arrowheads indicate endothelial staining and open arrow-
heads indicate epithelial staining.1745 Yang et al.
fect in the ability of CD41 T cells to respond to antigen.
Wild-type and p502/2 mice were immunized with OVA in-
traperitoneally and recall proliferative responses of spleen
CD41  T cells were analyzed by [3H]thymidine incorporation.
CD41 T cells from the p502/2 mice displayed a lower basal
incorporation (z50%) compared with those isolated from the
wild-type mice. However, they proliferated as efficiently as
the wild-type cells in response to antigen (Fig. 6 A).
Cytokine production was measured in culture superna-
tants and RNA was isolated from the OVA-restimulated
cells for analysis by RT-PCR. IL-2, IL-4, and IFN-g were
detected in the supernatants of cells derived from both
wild-type and p502/2 mice (Fig. 6 B). Interestingly, CD41
T cells from the p502/2 mice produced z5–7-fold more
IL-2 than did cells from wild-type mice. The most striking
difference was the total absence of IL-5 production by p50-
deficient T cells (Fig. 6 B). RT-PCR analysis of RNA
isolated from the OVA-stimulated CD41 T cells revealed
IL-4 RNA expression in both wild-type and p50-deficient
T cells (Fig. 6 C). The same RNA samples when analyzed
for IL-5 mRNA expression revealed expression in the
wild-type CD41 T cells with barely detectable expression
in the p50-deficient T cells (Fig. 6 C). 
Discussion
The molecular mechanisms that regulate eosinophilic in-
flammation in asthma is an area of intense investigation in
many laboratories. We have recently shown that the tran-
scription factor GATA-3 is expressed in Th2 but not Th1
cells and plays a critical role in IL-5 gene expression (46–
48). In this study, we have investigated the role of NF-kB
in the elicitation of eosinophilic inflammation in a murine
model of allergic airway inflammation. We show that the
absence of NF-kB abolishes airway inflammation. This re-
sults from the absence of IL-5 and eotaxin gene expression
in the p502/2 mice, both of which are key mediators of
eosinophilic inflammation in the airways. We also show
markedly attenuated lymphocyte recruitment in the lungs
of p502/2 mice that, in part, may be due to deficient ex-
pression of the chemokine genes MIP-1a and MIP-1b in
the p502/2 mice. These results provide the first in vivo evi-
Figure 5. Absence of induction of eotaxin, MIP-1a, and MIP-1b
mRNA in the lungs of p502/2 mice upon challenge with OVA. (A)
Chemokine mRNA expression was determined by RNase protection as-
says using the multiprobe template set mCK-5 (PharMingen) as described
in Materials and Methods. Each lane is representative of four mice and the
experiment was repeated three times with consistent results. (B) Estima-
tion of eotaxin protein in BALF by ELISA. Results shown are mean 6
SEM for four mice in each group. The significance of difference between
the two groups was analyzed using Student’s unpaired t test. Differences
in means were considered significant if P , 0.05. *P , 0.0001 compared
with protein levels in p501/1 mice.
Figure 6. Similar proliferative responses of CD41 T cells isolated from
p501/1 and p502/2 mice. (A) p501/1 (open symbols) and p502/2 (filled sym-
bols) mice were sensitized with OVA1alum on days 0 and 5, and on day
12 splenic T cells isolated from these mice were stimulated in vitro with
different concentrations of OVA (0.1–100 mg/ml). Cells were pulsed
with [3H]thymidine and incorporated counts were determined. Results
shown are mean 6 SEM. Shown is a representative experiment of two.
(B) Culture supernatants of cells stimulated with 100 mg/ml of OVA for
72 h were used for cytokine estimations by ELISA and the cells were har-
vested for RNA isolation for RT-PCR analysis. (C) PCR was carried out
for 35 cycles. The IL-4 and IL-5 PCR products were 240 and 251 bp, re-
spectively.1746 NF-kB Is Essential for Allergic Airway Inflammation
dence that NF-kB is required for the development of eosin-
ophilic inflammation in response to inhaled allergens.
Airway inflammation in asthma and allergic disease is a
complex phenomenon driven predominantly by Th2-type
cells. The inflammation is characterized by the recruitment
of leukocytes, predominantly eosinophils, and their subse-
quent migration from the vasculature into the tissue where
they cause severe damage to the bronchiolar epithelium (2,
4–10). Th2, epithelial, and endothelial cells play major
roles in this cascade by secreting cytokines and chemokines
and by expressing cell surface adhesion molecules. Since
multiple in vitro studies have implicated NF-kB in the ex-
pression of many of these molecules (24–26, 28, 29), we
examined the role of this transcription factor in eosino-
philic inflammation after antigen provocation. We show
that NF-kB plays a critical regulatory role in promoting
eosinophilia in vivo.
The phenotype of the p502/2 mice with respect to in-
flammation was in sharp contrast to the recently reported
phenotype of animals lacking the precursor p105 but ex-
pressing p50 (34). p50 is generated by proteolytic removal
of the COOH terminus of a precursor protein p105. The
murine nfkb1 gene produces two transcripts, a longer 4.0-
kb transcript that encodes the full-length precursor p105
and a shorter 2.6-kb mRNA that encodes the IkBg protein
that is identical to the COOH terminus of p105 that is
cleaved off to generate mature p50 (49, 50). Mice targeted
to lack p105 but containing p50 showed multiple abnor-
malities, including inflammation in the lungs and liver
composed largely of lymphocytes, increased susceptibility
to opportunistic infections, splenomegaly, lymph node
enlargement, and lymphoid hyperplasia (34). Since the
COOH terminus of p105 has an inhibitory effect on p50
homodimer activity, mice lacking p105 had an enhanced
p50 homodimer activity (34). Although excess (p50)2
present in p1052/2 mice resulted in decreased cytokine
production (IL-2 and IL-4) by stimulated T cells isolated
from these mice, T cell–dependent immune responses
overall were not seriously impaired in the p1052/2 mice
(34). In contrast, we demonstrate a severe impairment of T
cell–dependent eosinophilic inflammation in the p502/2
mice. It should be noted that although the p1052/2 mice
have excess (p50)2 together with, potentially, a small in-
crease in p50–p65 heterodimers, the p502/2 mice are de-
void of both (p50)2 and p50–p65 dimers. Thus, the net ef-
fect in the p502/2 mice is a combination of deficient p50
homo- and heterodimeric activity.
The absence of eosinophilic inflammation in the p502/2
mice did not result from a deficiency in the expression of
the cell adhesion molecules VCAM-1 and ICAM-1, which
have been shown to be important for the extravasation of
eosinophils into the lungs in models of airway inflamma-
tion. Many in vitro studies have implicated NF-kB in the
transcriptional regulation of VCAM-1 (51–53) and ICAM-1
(53–55) genes in endothelial cells. Therefore, it was surpris-
ing that p50 deficiency did not abolish the expression of
these molecules since these mice lack not only (p50)2 but
also the p50–p65 heterodimer, which is the predominant
NF-kB transactivator. In addition to the p50–p65 het-
erodimer, (p65)2 has been shown also to be a potent transac-
tivator, although it is found in much lower abundance than
the p50–p65 heterodimer (30). Indeed, a few studies pro-
pose a more important role for the (p65)2 rather than the
p50–p65 heterodimer in IL-1 or TNF-induced VCAM-1
(56, 57) and ICAM-1 (58) gene expression. Interestingly, in
one study, IL-4–induced VCAM-1 gene expression was
shown to involve an NF-kB–independent mechanism (59).
Our studies suggest that the expression of VCAM-1 and
ICAM-1 in this allergen model of airway inflammation is
not critically dependent on the p50–p65 heterodimer.
The lungs of the p502/2 mice were indistinguishable
from the lungs of either sham-immunized or unchallenged
animals and did not display an easily discernible increase in
eosinophil, neutrophil, or lymphocyte infiltration after an-
tigen challenge. Leukocyte infiltration into sites of inflam-
mation is now known to involve cytokine-inducible chemo-
attractants called chemokines. Chemokines that have been
implicated in the recruitment of activated CD41 T cells to
inflammatory sites include RANTES, MIP-1a, MIP-1b
(60), and IP-10 (the murine homologue is Crg-2; reference
61). In this model we and others have detected a low level
constitutive expression of RANTES mRNA that did not
increase after antigen challenge (62). The induction of
MIP-1a and MIP-1b mRNA was abolished in the p502/2
mice, suggesting that the induction of these chemokines in
vivo is an NF-kB–dependent process, at least in this model.
The lack of expression of the MIP-1a and MIP-1b genes
may be partly responsible for the reduced number of lym-
phocytes in the lungs of p50-deficient mice. In contrast to
lack of induction of eotaxin, MIP-1a and MIP-1b mRNA
in the p50-deficient animals, the steady-state level of IP-10
mRNA was greater in the lungs of antigen-challenged
p502/2 mice compared with that in the lungs of similarly
challenged wild-type mice. We have not determined the
cellular source of IP-10 in the lungs of these mice, but the
likely candidates are activated macrophages and/or endo-
thelial cells. CXCR3, the receptor for IP-10, has been
shown to be predominantly expressed by human Th1 cells
(63). If the same is true in mice, then despite increased ex-
pression of IP-10 in p502/2 mice, this chemokine was inef-
fective in the recruitment of Th2-type cells to the lung due
to the absence of the cognate receptor on the Th2 cells.
Recently, a subset of human Th2 cells were shown to ex-
press the chemokine receptor CCR3 (63–66), the best de-
scribed ligand for which is eotaxin. CCR3 is also highly
expressed on the cell surface of both murine and human
eosinophils (67–69) and accounts for the specific chemo-
tactic effects of eotaxin on eosinophils. Although a role for
eotaxin in Th2 cell chemotaxis has not been demonstrated,
it is suggested that eotaxin may control the trafficking of a
subset of Th2s that stimulate growth and activation of
colocalized eosinophils and basophils (65, 66, 70). Thus,
the absence of key chemokines that have been shown to be
important for the recruitment of activated CD41 T cells
probably explains the reduced T cell infiltration into the
lungs of antigen-challenged p502/2 mice.1747 Yang et al.
An important difference between the wild-type mice
and the p502/2 mice was the lack of eotaxin and IL-5 gene
expression in the p50-deficient animals. Eotaxin has been
shown to be a specific chemoattractant for eosinophils in
different species including the guinea pig, mouse, and hu-
man (71–73). The in vivo specificity and potency of eo-
taxin for eosinophil chemotaxis were demonstrated in stud-
ies showing eosinophil recruitment into tissue either after
instillation of eotaxin into the airways or after injection
into the skin (73–77). Eotaxin is produced in large quanti-
ties by the type I cells in the alveolar epithelium, although
other cells such as endothelial cells and the infiltrating eosin-
ophils are also known to produce eotaxin (73–75). In vivo,
the production of eotaxin has been shown to be dependent
on T cells (62). Using the OVA model of airway inflamma-
tion, MacLean et al. have shown a profound inhibition of
eotaxin but not RANTES or MIP-1a production in mice
treated with anti-CD3 antibody (62). The molecular basis
for this effect is unclear. However, it is possible that eotaxin
production upon allergen challenge is induced by a T cell–
derived cytokine, most likely a Th2 cytokine. Since, in ad-
dition to eotaxin, the p502/2 mice also do not produce IL-5,
it is possible that IL-5 is a necessary stimulus for the induc-
tion of eotaxin gene expression in this model of airway in-
flammation. A nonmutually exclusive explanation for the
lack of eotaxin gene transcription in p502/2 mice is that
eotaxin gene expression is directly regulated by NF-kB. In-
deed, the 59 flanking region of the eotaxin gene contains
NF-kB sites, although their functional significance has yet
to be determined (78). It is now believed that eosinophil
chemotaxis involves cooperation between IL-5 and eotaxin
as shown in the guinea pig and mouse (23, 76, 79, 80).
IL-5 and eotaxin are both produced in the lung, the major
source of IL-5 being Th2 cells. IL-5 secreted by Th2 cells is
transported by the blood to the bone marrow. A major role
of IL-5 at this step is to trigger a rapid mobilization of eosin-
ophils and progenitors from the bone marrow into the
blood since this process is inhibited upon treatment with
the anti–IL-5 antibody TRFK5 (79). The role of eotaxin is
to recruit the eosinophils from the vasculature. Thus, given
the important role of IL-5 and eotaxin in eosinophil re-
cruitment to the lungs in allergic inflammation, the com-
bined deficiency of both of these factors in the p50-defi-
cient animals could explain the total abrogation of airway
eosinophilia in these mice.
In this study, we also show that the absence of NF-kB
influences T cell cytokine gene expression. Different in
vitro studies have suggested a role for NF-kB in the ex-
pression of the IL-2 gene. Although the p50–p65 het-
erodimer has been shown to interact with an NF-kB site in
the IL-2 promoter, (p50)2 has been shown to function as a
repressor of IL-2 gene expression (31). In our studies, not
only was IL-2 produced by the p50-deficient cells, the
amount of IL-2 secreted by these cells was z5–7-fold
greater than that produced by the wild-type T cells. This
suggests, first, that (p65)2 or other Rel dimers can substitute
for the classic NF-kB dimer for transactivation of the IL-2
gene in this model. Second, our studies support the data of
Kang et al. (31) that an essential turn-off signal for IL-2
gene transcription is (p50)2 since the p502/2 mice produced
considerably more IL-2 than did the wild-type mice. Con-
versely, in p1052/2 mice, which have excess (p50)2, IL-2
gene expression was found to be three- to sixfold lower
than that in wild-type mice (34). Although no difference
was noted between the wild-type and p50-deficient T cells
with respect to the net fold-stimulation of the cells upon
antigen challenge, the basal [3H]thymidine incorporation
by the p50-deficient cells was z50% of that of the wild-
type cells. This may be due to a lower basal expression of
the IL-2 or the IL-2Ra gene (whose expression is also be-
lieved to be under NF-kB control) in the absence of the
classic NF-kB dimer. We show that the absence of p50
profoundly inhibits IL-5 gene expression in CD41 T cells.
Presently, it is unclear whether this is due to a primary or
secondary effect of NF-kB on IL-5 gene expression.
An important outcome of this study is the differential ef-
fect of NF-kB on IL-4 and IL-5 gene expression. There is
increasing interest in the dissociation of IL-4 and IL-5 gene
expression in T cells in various disease situations and in T
cell lineages (for review see references 81, 82). For exam-
ple, in intrinsic asthmatics, IL-5 but not IL-4 production is
elevated (83). In contrast, in leukemic Sezary cells, IL-4 has
been shown to be upregulated with concomitant decrease
in IL-5 production (84). Again, in a study of human T cells
using intracellular staining techniques, IL-4 and IL-5 were
found to be predominantly made by different cells (85).
There is no evidence to date that supports different lineage
of cells for IL-4 and IL-5 production. However, it is rea-
sonable to speculate that once cells have been committed to
the Th2 lineage, different microenvironmental factors acti-
vate different sets of transcription factors such as NF-kB,
GATA-3 (46, 47, 86, 87), c-maf (88), and NF-AT (89),
which have differential effects on IL-4 and IL-5 gene ex-
pression. We have recently shown that ectopically ex-
pressed GATA-3 is sufficient for IL-5 but not IL-4 gene
expression (48). Thus, our studies provide clear evidence
that although IL-4 and IL-5 are often coordinately ex-
pressed, the absence of transcription factors such as NF-kB
can cause selective impairment of IL-5 but not IL-4 gene
expression. The attenuation of both IL-5 and eotaxin gene
expression in p502/2 mice establishes a central role for NF-
kB in airway eosinophilia in allergic inflammation.
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